Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961668 | 0.90 | SIGMAR1 (0.46) | NLRP3SIGMAR1HDAC6CTBP2DYRK2 | |
| SCHEMBL13199083 | 0.84 | SIGMAR1 (0.42) | NLRP3SIGMAR1CTBP2DYRK2PDCD1 | |
| SCHEMBL13199068 | 0.84 | LMNA (0.53) | NLRP3KMT2ASIGMAR1CTBP2PDCD1 | |
| SCHEMBL2962400 | 0.84 | SIGMAR1 (0.44) | NLRP3KMT2ASIGMAR1CTBP2DYRK2 | |
| SCHEMBL13199071 | 0.83 | SIGMAR1 (0.41) | NLRP3SIGMAR1CTBP2DYRK2PDCD1 | |
| SCHEMBL13199076 | 0.80 | PTPN1 (0.50) | NLRP3SIGMAR1DYRK2PDCD1CD274 | |
| SCHEMBL2954101 | 0.78 | NLRP3 (0.45) | NLRP3SIGMAR1PDCD1CD274ANO1 | |
| SCHEMBL13199254 | 0.78 | SMPD1 (0.43) | KMT2ASIGMAR1HDAC6LMNAGAA | |
| SCHEMBL13199211 | 0.78 | NPC1 (0.46) | NLRP3SIGMAR1HDAC6CTBP2DYRK2 | |
| SCHEMBL13199067 | 0.78 | GFER (0.53) | KMT2ADYRK2PDCD1CD274LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767716-B2 | Acyl hydrazines as kinase inhibitors, in particular for SGK | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767716-B2 | Acyl hydrazines as kinase inhibitors, in particular for SGK | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| EP-1866280-B1 | ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK | MERCK PATENT GMBH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080167380-A1 | Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167380-A1 | Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167380-A1 | Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk | SGK1, AGK, SGK2 | NLRP3 3060/4885KMT2A 1190/4885SIGMAR1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.